Micro Lab #4 - Moving from Experimental Success to Clinical RealityDate/Time: September 30, 2021, from 11AM to 2PM EST.
There are many promising drug combinations resulting from computational or in vitro assays that fail to translate to the clinic. The reasons can be diverse and include toxicity but also PK and factors that are patient-specific. Is it possible to incorporate this information earlier in the process? We will discuss this and other questions including but not limited to:
How should cell toxicity and side effects balance therapeutic efficiency?
Can we explain synergistic differences between toxicity and efficacy?
How does heterogeneity of the patient population hinder or help these predictions?
What experimental systems can be used to predict the toxicity/efficacy trade-off?
Cancer Biology Perspective
Computational Modeling Perspective
Bristol Myers Squibb